Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-Controlled, Multi-center Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

NCT07724340 is registered in ClinicalTrials.gov with Antag Therapeutics as lead sponsor.

NCT NCT07724340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07724340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-Controlled, Multi-center Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
Lead sponsor
Antag Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 19, 2026
Completion date
March 31, 2027
Enrollment
150 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

adults with overweight/obesity and type 2 diabetes